amitriptyline has been researched along with Migraine Disorders in 144 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The tricyclic antidepressant amitriptyline (AMT) and the calcium channel blocker flunarizine are frequently used in the preventive treatment of migraine, but the side-effect of prominent weight gain that frequently emerges during preventive treatment of migraine with these agents often leads to the discontinuation of therapy." | 9.11 | Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. ( Berilgen, MS; Bulut, S; Dag, E; Gonen, M; Mungen, B; Tekatas, A, 2005) |
| "Headache is one of the most frequently reported symptoms in post-COVID patients." | 5.72 | Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors. ( Arias-Rivas, S; Gago-Veiga, AB; García-Azorín, D; Gonzalez-Martinez, A; Guerrero-Peral, ÁL; Sierra, Á; Silva, L, 2022) |
| "The patient was diagnosed with probable chronic paroxysmal hemicrania in accordance with the International Classification of Headache Disorders (ICHD-3) (third version)." | 5.72 | A Combination of Indomethacin Farnesyl and Amitriptyline Is Effective for Continuous Interictal Pain with Probable Chronic Paroxysmal Hemicrania. ( Danno, D; Kashiwaya, Y; Kikui, S; Kohashi, M; Miyahara, J; Ota, K; Sugiyama, H; Takeshima, T, 2022) |
| "Explore predictors of improvement in headache days and migraine-related disability through a secondary analysis of the cognitive-behavioral therapy plus amitriptyline trial in children and adolescents (Clinical Trials Registration Number: NCT00389038)." | 5.51 | Predictors of Improvement in Pediatric Chronic Migraine: Results from the Cognitive-Behavioral Therapy and Amitriptyline Trial. ( Ergun, G; Hershey, AD; Kabbouche, MA; Kacperski, J; LeCates, SL; Powers, SW; Rettig, EK; Slater, SK; Warfield, JR, 2022) |
| " Childhood and Adolescent Migraine Prevention study participants completed headache diaries during a 28-day baseline period and a 168-day active treatment period during which youth took amitriptyline, topiramate, or placebo." | 5.51 | Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial. ( Chamberlin, LA; Coffey, CS; Ecklund, DJ; Hershey, AD; Kabbouche, MA; Kacperski, J; Klingner, EA; Korbee, LL; Peugh, J; Porter, LL; Powers, SW; Reidy, BL; Yankey, JW, 2022) |
| " Participants were randomly assigned to cognitive-behavioral therapy plus amitriptyline (CBT+A, N=64) or headache education plus amitriptyline (HE+A, N=71)." | 5.24 | Treatment Adherence in Child and Adolescent Chronic Migraine Patients: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial. ( Allen, JR; Hershey, AD; Hommel, K; Kabbouche, MA; Kacperski, J; Kashikar-Zuck, S; Kroner, JW; Kroon Van Diest, AM; LeCates, S; O'Brien, HL; Peugh, J; Powers, SW; Ramsey, RR; Slater, S, 2017) |
| "To determine the benefits of cognitive behavioral therapy (CBT) when combined with amitriptyline vs headache education plus amitriptyline." | 5.17 | Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. ( Allen, JR; Hershey, AD; Kabbouche, MA; Kashikar-Zuck, SM; LeCates, SL; O'Brien, HL; Powers, SW; Rausch, JR; Shenk, CE; Slater, SK; Zafar, M, 2013) |
| "The tricyclic antidepressant amitriptyline (AMT) and the calcium channel blocker flunarizine are frequently used in the preventive treatment of migraine, but the side-effect of prominent weight gain that frequently emerges during preventive treatment of migraine with these agents often leads to the discontinuation of therapy." | 5.11 | Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. ( Berilgen, MS; Bulut, S; Dag, E; Gonen, M; Mungen, B; Tekatas, A, 2005) |
| "In this study fibromyalgia sufferers were randomly administered a combination of monoamine-oxidase inhibitors (MAOIs)-A/B with 5-HTP, 5-HTP alone, MAOIs-A/B alone, or the tricyclic drug amitriptyline in order to compare the efficacy of these treatments." | 5.08 | Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. ( Nicolodi, M; Sicuteri, F, 1996) |
| " On the other hand, patients with divalproex exhibited significantly higher risk of nausea compared to those with placebo, topiramate, propranolol, gabapentin and amitriptyline." | 4.95 | Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. ( He, A; Li, C; Song, D; Zhang, L, 2017) |
| " The workup included an endocrinological examination, which revealed a moderately elevated urine normetanephrine level, suggesting the possibility of a pheochromocytoma." | 3.80 | Obstructive sleep apnea and tricyclic antidepressant use presenting as a pseudopheochromocytoma in an active duty sailor: a case report. ( Brainard, T, 2014) |
| "Children aged 16 years or less with first diagnosed of either migraine or tension-type headache were reassured the cause of headache and treated by avoiding triggering factors, taking intermittent analgesics or a daily preventive medication such as propanolol 10 mg two times a day or amitriptyline 10 mg at night for patients who were suffered from the frequent headache attacks whether had to stop activity or go to sleep." | 3.74 | Short-term outcomes of tension type and migraine headache in children. ( Ruangsuwan, S; Sri-udomkajorn, S, 2008) |
| "Self-reported and "nosology-derived" migraine days during the baseline and treatment phases were strongly associated (r's = 0." | 3.30 | Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments. ( Chamberlin, LA; Coffey, CS; Ecklund, D; Gibler, RC; Hershey, AD; Kabbouche, M; Kacperski, J; Klingner, E; Korbee, LL; Peugh, JL; Porter, LL; Powers, SW; Reidy, BL; Yankey, J, 2023) |
| "Patients with complaints of migraine attacks were randomly divided into two groups." | 3.11 | Venlafaxine can reduce the migraine attacks as well as amitriptyline: A noninferiority randomized trial. ( Hedayat, M; Heidari, M; Nazarbaghi, S; Sharifi, H, 2022) |
| "Amitriptyline was prescribed in a dose of 10mg, increased to 25mg after 2 weeks; thereafter increase in dose to 50 mg was optional." | 3.01 | A Randomized Controlled Trial of High Rate rTMS Versus rTMS and Amitriptyline in Chronic Migraine. ( Kalita, J; Kumar, S; Misra, UK; Singh, VK, 2021) |
| "Consecutive patients with migraine were randomized to receive 25 mg of amitriptyline/day (n = 34), NTI-tss (n = 33) and a non-occlusal splint (n = 30)." | 2.87 | Amitriptyline and intraoral devices for migraine prevention: a randomized comparative trial. ( Bruno, MAD; Krymchantowski, AV, 2018) |
| "12%) in the amitriptyline group and paresthesia (31% vs." | 2.84 | Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. ( Chamberlin, LA; Coffey, CS; Ecklund, DJ; Hershey, AD; Klingner, EA; Korbee, LL; Porter, LL; Powers, SW; Yankey, JW, 2017) |
| "Youth with chronic migraine who received CBT+A improved faster than those in the control group." | 2.84 | Trajectory of Improvement in Children and Adolescents With Chronic Migraine: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial. ( Allen, JR; Hershey, AD; Kabbouche, MA; Kashikar-Zuck, SM; Kroner, JW; Kroon Van Diest, AM; LeCates, SL; O'Brien, HL; Peugh, J; Powers, SW; Shenk, CE; Slater, SK; Zafar, M, 2017) |
| "Chronic migraine negatively affects children's home, school, and social activities." | 2.82 | Cognitive Behavioral Therapy plus Amitriptyline for Children and Adolescents with Chronic Migraine Reduces Headache Days to ≤4 Per Month. ( Allen, JR; Hershey, AD; Kabbouche, MA; Kashikar-Zuck, SM; Kroner, JW; Kroon Van Diest, AM; LeCates, SL; O'Brien, HL; Powers, SW; Rausch, JR; Shenk, CE; Slater, SK; Zafar, M, 2016) |
| "Studies that compared the efficacy of migraine medications (topiramate, amitriptyline) to exercise were included." | 2.82 | What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials. ( Oliveira, ABD; Woldeamanuel, YW, 2022) |
| " There was no significant difference in the occurrence of common adverse drug reactions, such as drowsiness and fatigue, between the melatonin group and the comparison groups." | 2.82 | Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis. ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Puliappadamb, HM, 2022) |
| "Melatonin was superior to amitriptyline in the percentage of patients with a greater than 50% reduction in migraine frequency." | 2.82 | Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. ( Cipolla-Neto, J; Gonçalves, AL; Martini Ferreira, A; Peres, MF; Ribeiro, RT; Zukerman, E, 2016) |
| "Vitamin D given in addition to anti-migraine treatment reduced the number of migraine attacks." | 2.79 | Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. ( Cayir, A; Tan, H; Turan, MI, 2014) |
| "The aim of the Childhood and Adolescent Migraine Prevention (CHAMP) study is to determine the most effective preventive agent to use in children and adolescents." | 2.78 | Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. ( Chamberlin, LA; Coffey, CS; Eklund, DD; Hershey, AD; Korbee, LL; Powers, SW, 2013) |
| "We report the predictors of allodynia in migraine and the effect of divalproate or amitriptyline in alleviating allodynia." | 2.78 | Allodynia in migraine: clinical observation and role of prophylactic therapy. ( Bhoi, SK; Kalita, J; Misra, UK, 2013) |
| "Three hundred migraineurs having >4 attacks monthly were randomized into DVA-ER or AMT." | 2.78 | Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. ( Bhoi, SK; Kalita, J; Misra, UK, 2013) |
| "Thirty-nine migraine patients with a body mass index <25 kg/m(2) and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months." | 2.76 | Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. ( Calabresi, P; Caproni, S; Corbelli, I; Cupini, ML; Pini, LA; Sarchielli, P, 2011) |
| "Amitriptyline was superior to placebo in number with improvement in frequency of ≥ 50% at 8 weeks (25% vs 5% [P = ." | 2.76 | Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. ( Couch, JR, 2011) |
| "Chronic migraine sufferers were randomized into two groups and treated with 25 or 50mg/day of amitriptyline or 250U of botulinum toxin type A." | 2.75 | Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. ( Cardeal, M; Magalhães, E; Melo, A; Menezes, C, 2010) |
| "Topiramate was associated with improvement in some quality-of-life indicators compared with amitriptyline and was associated with weight loss and improved weight satisfaction." | 2.74 | Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. ( Banks, J; Biondi, D; Dodick, DW; Freitag, F; Greenberg, SJ; Hulihan, J; Rupnow, M; Saper, J; Xiang, J, 2009) |
| "Median migraine days per month were reduced from 7 days (range: 6-15) at baseline, to 6 days (range: 4-12; P < 0." | 2.74 | Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. ( Adl, J; Baumhackl, U; Franz, G; Huber, G; Lampl, C; Luthringshausen, G; Marecek, S; Mueller, T; Weber, J, 2009) |
| "Migraine, particularly migraine with aura, and increased body weight are independent risk factors for cardiovascular disease (CVD)." | 2.74 | Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine. ( Bigal, ME; Biondi, DM; Hulihan, J; Lipton, RB; Xiang, J, 2009) |
| "A total of 73 patients with migraine headache with or without aura are included in this single-center, double-blind, randomized, and controlled trial." | 2.73 | A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. ( Aydinli, I; Keskinbora, K, 2008) |
| "Taking into account that migraine is associated with major depression, in the present research the effect of the antidepressant amitriptyline was also evaluated." | 2.73 | Emotional memory and migraine: effects of amitriptyline and sex related difference. ( Arnone, B; Cifariello, A; Gasbarri, A; Marini, C; Pompili, A; Tavares, MC; Tomaz, C, 2008) |
| "In patients with migraine with or without aura the prophylactic effect of amitriptyline (AMT) and venlafaxine (VLF) was compared in a randomized double-blind crossover study." | 2.71 | Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. ( Atmaca, M; Baran, A; Berilgen, MS; Bulut, S; Mungen, B; Tekatas, A, 2004) |
| "Amitriptyline was dosed as follows: 8 mg/day for 6 days, 8 mg twice a day for 6 days, 20 mg/day for 6 days, and 20 mg twice a day for 45 days." | 2.70 | Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. ( Alves, LA; Barbosa, JS; Krymchantowski, AV; Silva, MT, 2002) |
| "The duration of the therapy of migraine between the attacks was 12 weeks." | 2.69 | [A comparative efficiency of amitriptyline, fluoxetine and maprotiline in prevention of migraine in attack-free period]. ( Amelin, AV; Gonchar, MA; Korenko, LA; Skoromets, AA; Tumelevich, BCh, 2000) |
| "Migraine headache affects approximately 11 million adults in the United States." | 2.69 | The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. ( Anderson, AV; Boline, P; Bronfort, G; Evans, R; Goldsmith, C; Nelson, CF, 1998) |
| "Amitriptyline response was correlated with female gender and baseline headaches of shortest duration and of highest frequency." | 2.67 | Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. ( Hassanein, R; Hurwitz, A; Preskorn, S; Seim, J; Ziegler, DK, 1993) |
| "Current treatment of migraine either abortive or prophylactic is often unsatisfactory." | 2.67 | A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. ( Bánk, J, 1994) |
| "Mood disturbances accompanying migraine syndromes suggest a mode of action of such a class of drugs." | 2.66 | Antidepressant drugs and migraine. ( Agnoli, A; Manna, V; Martucci, N, 1985) |
| "Nondepressed subjects with severe migraine and depressed subjects with less severe migraine responded best to amitriptyline, whereas depressed subjects with severe migraine had little headache relief." | 2.65 | Amitriptyline in migraine prophylaxis. ( Couch, JR; Hassanein, RS, 1979) |
| "Amitriptyline was found to have the greatest effect in reducing attacks with a short warning and in which no specific cause could be recognized." | 2.64 | Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. ( Gomersall, JD; Stuart, A, 1973) |
| "The treatment of headache is usually successful and thus highly rewarding for physicians of all medical specialties." | 2.58 | Hints on Diagnosing and Treating Headache. ( May, A, 2018) |
| "Migraine is a disabling and prevalent condition that affects the pediatric and adolescent population." | 2.58 | The Changing Landscape of Pediatric Migraine Therapy: A Review. ( Patterson-Gentile, C; Szperka, CL, 2018) |
| "The Childhood and Adolescent Migraine Prevention Study (CHAMP) was developed to examine the effectiveness of two of the most widely prescribed preventive medications for pediatric migraine and help narrow this gap." | 2.55 | New Developments in the Prophylactic Drug Treatment of Pediatric Migraine: What Is New in 2017 and Where Does It Leave Us? ( Bazarsky, A; Kacperski, J, 2017) |
| "Mild migraine attack can be treated with acetaminophen or NSAIDs either alone or combined with metoclopramide." | 2.52 | [Update on Current Care Guideline: Migraine]. ( , 2015) |
| "We define chronic migraine as that clinical situation in which migraine attacks appear 15 or more days per month." | 2.48 | [Chronic migraine: treatment]. ( Pascual, J, 2012) |
| "However, migraine remains underdiagnosed, and patients with migraine remain undertreated." | 2.44 | Diagnosing and managing migraine headache. ( Mueller, LL, 2007) |
| "Drug prevention of migraine is recommended if more than three attacks occur per month, acute drug treatment is insufficient, or very severe attacks with aura are the main problem." | 2.44 | [Alternatives to beta blockers in preventive migraine treatment]. ( Evers, S, 2008) |
| "The association of migraine and depression has been confirmed in numerous studies and it has been suggested that both diseases influence each other in a bidirectional way." | 2.44 | [A clinical challenge. Pragmatic treatment of migraine and concomitant depression]. ( Jürgens, TP; Koch, HJ; Leinisch, E, 2008) |
| "In over 40% of migraineurs the condition begins before 18 years of age." | 2.42 | Primary headaches in children and adolescents. ( Grazzi, L, 2004) |
| "For example, a hypertensive migraine sufferers may benefit from betablockers; in a patient who suffers both from migraine and tension type headaches or from depression, amitriptyline is the first choice drug." | 2.41 | [Prophylactic treatments of migraine]. ( Massiou, H, 2000) |
| "Neurologists and PCPs chose migraine prophylaxis on the basis of scientific merit (r = 0." | 2.40 | Migraine prophylactic drugs: proof of efficacy, utilization and cost. ( Gilkey, SJ; Ramadan, NM; Schultz, LL, 1997) |
| "He discusses treatment of headache in relation to management of the acute attack, avoidance of trigger factors, and pharmacological and nonpharmacological prophylaxis." | 2.37 | An overview of the classification, causes, and treatment of headache. ( Ziegler, DK, 1984) |
| "Headache is one of the most frequently reported symptoms in post-COVID patients." | 1.72 | Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors. ( Arias-Rivas, S; Gago-Veiga, AB; García-Azorín, D; Gonzalez-Martinez, A; Guerrero-Peral, ÁL; Sierra, Á; Silva, L, 2022) |
| "The patient was diagnosed with probable chronic paroxysmal hemicrania in accordance with the International Classification of Headache Disorders (ICHD-3) (third version)." | 1.72 | A Combination of Indomethacin Farnesyl and Amitriptyline Is Effective for Continuous Interictal Pain with Probable Chronic Paroxysmal Hemicrania. ( Danno, D; Kashiwaya, Y; Kikui, S; Kohashi, M; Miyahara, J; Ota, K; Sugiyama, H; Takeshima, T, 2022) |
| "Vestibular migraine (VM) consists of recurrent episodes of vestibular symptoms that are accompanied by migraine in at least 50% of the episodes." | 1.56 | Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug. ( Álvarez-Morujo de Sande, MG; Bécares-Martínez, C; Domènech-Vadillo, E; Domínguez-Durán, E; González-Aguado, R; Guerra-Jiménez, G; Montilla-Ibáñez, MA, 2020) |
| "The role of oxidative stress markers in migraine and effect of treatment on these has been reported." | 1.48 | A study of oxidative stress in migraine with special reference to prophylactic therapy. ( Kalita, J; Misra, UK; Tripathi, GM, 2018) |
| "Certain medications used for migraine prevention in adults do not perform the same way in children and adolescents and can actually cause harm." | 1.48 | PURL: Treating migraines: It's different for kids. ( Hawks, M; Mounsey, A, 2018) |
| "Glutamate plays an important role in migraine pathogenesis but there is paucity of studies on glutamate in migraine subtypes, effect of treatment on glutamate levels and the changes in glutamate receptors." | 1.48 | Role of glutamate and its receptors in migraine with reference to amitriptyline and transcranial magnetic stimulation therapy. ( Kalita, J; Misra, UK; Tripathi, GM, 2018) |
| "The medical files of patients with migraine attending the headache clinic of a tertiary pediatric medical center in 2010-2015 were reviewed." | 1.43 | Factors Influencing Response to Pharmacologic Treatment of Migraine in a Pediatric Headache Clinic. ( Haimi-Cohen, Y; Markus, TE; Moad, B; Zeharia, A, 2016) |
| "Prophylactic therapy response varies in migraine patients." | 1.43 | Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. ( Ak, S; Atasayar, G; Can, FE; Cecener, G; Egeli, U; Eryilmaz, IE; Karli, N; Taskapilioglu, O; Tezcan, G; Tunca, B; Yildirim, O; Zarifoglu, M, 2016) |
| "Evidence-based interventions for migraine should have as much a claim on scarce health resources as those for other chronic, non-communicable conditions that impose a significant burden on societies." | 1.42 | Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. ( Chisholm, D; Linde, M; Steiner, TJ, 2015) |
| "Recent evidence suggests that facial pain may not be related to the sinuses at all and that doctors may have to rethink their prescribing strategy." | 1.40 | Is 'sinus' pain really sinusitis? ( Agius, AM; Jones, NS; Muscat, R, 2014) |
| "Chronic nausea is a major, disabling symptom that requires increased recognition as a separate functional entity." | 1.40 | Chronic idiopathic nausea of childhood. ( Chelimsky, G; Kovacic, K; Li, BU; Miranda, A; Simpson, P; Williams, S, 2014) |
| "Status migrainosus (SM) and migraine aura status (MAS) are two migraine complications." | 1.40 | Status migrainosus and migraine aura status in a French tertiary-care center: An 11-year retrospective analysis. ( Beltramone, M; Donnet, A, 2014) |
| "Daily migraine medication prevention is indicated when migraine frequency and disability are high." | 1.36 | The role of prevention. ( Tepper, SJ, 2010) |
| "Amitriptyline (AMI) is widely used for migraine prophylaxis, but its mechanism is undetermined." | 1.36 | Amitriptyline inhibits currents and decreases the mRNA expression of voltage-gated sodium channels in cultured rat cortical neurons. ( Fu, Q; Wan, Q; Wang, Q; Xiao, H; Yan, L; Ye, Q, 2010) |
| "The surgical treatment of migraine headache is a recent innovation that has broadened the potential patient population who may benefit from craniofacial surgical techniques to millions of affected adults." | 1.35 | Review of pediatric migraine headaches refractory to medical management. ( Eshraghi, Y; Gosain, AK; Kung, TA; Scher, MS; Totonchi, A, 2009) |
| "Migraine is Europe and North America's most frequent neurological illness." | 1.35 | [Migraine in 2009: from attack to treatment]. ( Supiot, F, 2009) |
| "We present a novel case of migraine headache in a gentleman with Klinefelter's syndrome and HFI, along with a discussion of possible pathophysiologic mechanisms underlying both the headache and the HFI." | 1.34 | Headache in a patient with Klinefelter's syndrome and hyperostosis frontalis interna. ( Liebeskind, DS; Ramchandren, S, 2007) |
| "We describe an MS patient who developed migraine headaches, which followed a specific pattern coincident with interferon-beta administration." | 1.33 | Migraines linked to interferon-beta treatment of multiple sclerosis. ( Fast, A; Khromov, A; Nissinoff, J; Segal, M, 2005) |
| "Abdominal migraine is a rarely recognized functional intestinal disorder, manifesting as recurrent paroxysmal abdominal pain of neurogenic origin." | 1.33 | [Abdominal migraine as a cause of chronic recurrent abdominal pain in a 9-years-old girl--case report]. ( Karczewska, K; Kasner, J; Kwiecień, J; Piasecki, L, 2005) |
| "(6) Flunarizine also has documented efficacy, but this "hidden neuroleptic" can cause extrapyramidal disorders and weight gain." | 1.33 | Pharmacological prevention of migraine: to be considered case by case. ( , 2006) |
| "Amitriptyline was the most commonly prescribed agent (58%)." | 1.32 | Prophylactic treatment of pediatric migraine. ( Diamond, S; Jones, V; Lewis, DW; Scott, D, 2004) |
| "Adding a preventive medication to migraine management reduced the use of other migraine medications, as well as visits to physician offices and emergency departments." | 1.32 | Migraine preventive medication reduces resource utilization. ( Chmiel, JJ; Silberstein, SD; Winner, PK, 2003) |
| "A family history of migraine, primarily maternal, was found in 11 of 12 patients in whom it could be evaluated." | 1.29 | Migraine in the infant and toddler. ( Barlow, CF, 1994) |
| "The interactions of four abortive anti-migraine agents and four prophylactic anti-migraine agents with 5-HT1D receptors in bovine brain were analyzed using radioligand binding techniques and adenylate cyclase assays." | 1.28 | 5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy. ( Deliganis, AV; Peroutka, SJ, 1991) |
| "The nystagmus resolved when her classic migraine headaches were controlled with medical therapy." | 1.28 | Intermittent unidirectional nystagmus. ( Jay, WM; Nazarian, SM, 1990) |
| "The infants with ophthalmoplegic migraine failed to completely respond to any therapy." | 1.28 | Migraine headache in the infant and young child. ( Elser, JM; Woody, RC, 1990) |
| "The response to prophylactic anti-migraine medication (propranolol or amitriptyline used alone or in combination) was gratifying, with 21 of 30 adequately treated patients (70%) reporting dramatic reduction in the frequency and severity of their headaches." | 1.28 | Post-traumatic migraine: chronic migraine precipitated by minor head or neck trauma. ( Goldberg, J; Stern, BJ; Weiss, HD, 1991) |
| "In thirty patients with common migraine the platelet concentrations of met-enkephalin immunoreactivity (ME) (76 +/- 9 pg/mg protein) were similar to those in 23 healthy volunteers (77 +/- 5), suggesting that there is no alteration in the ME pool in this biochemical compartment in migraine." | 1.27 | Platelet met-enkephalin immunoreactivity and 5-hydroxytryptamine concentrations in migraine patients: effects of 5-hydroxytryptophan, amitriptyline and chlorimipramine treatment. ( Boiardi, A; Bussone, G; Di Giulio, AM; Galva, MD; La Mantia, L; Mantegazza, P; Picotti, GB, 1984) |
| "In the prophylaxis of migraine beta-blockers are commonly used." | 1.27 | Combination headache: practical experience with a combination of a beta-blocker and an antidepressive. ( Kellhammer, U; Pfaffenrath, V; Pöllmann, W, 1986) |
| "Benefits of migraine therapy include improvements in the patient's overall health and sense of well-being." | 1.27 | Management of the migraine patient. ( Gunderson, CH, 1986) |
| "Amitriptyline was evaluated as a prophylactic antimigraine agent in 110 patients with severe migraine." | 1.26 | Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. ( Couch, JR; Hassanein, R; Ziegler, DK, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (18.06) | 18.7374 |
| 1990's | 14 (9.72) | 18.2507 |
| 2000's | 40 (27.78) | 29.6817 |
| 2010's | 52 (36.11) | 24.3611 |
| 2020's | 12 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kalita, J | 5 |
| Kumar, S | 1 |
| Singh, VK | 1 |
| Misra, UK | 5 |
| Hedayat, M | 1 |
| Nazarbaghi, S | 1 |
| Heidari, M | 1 |
| Sharifi, H | 1 |
| Gonzalez-Martinez, A | 1 |
| Guerrero-Peral, ÁL | 1 |
| Arias-Rivas, S | 1 |
| Silva, L | 1 |
| Sierra, Á | 1 |
| Gago-Veiga, AB | 1 |
| García-Azorín, D | 1 |
| Woldeamanuel, YW | 1 |
| Oliveira, ABD | 1 |
| Puliappadamb, HM | 3 |
| Maiti, R | 3 |
| Mishra, A | 3 |
| Jena, M | 3 |
| Mishra, BR | 3 |
| Gibler, RC | 1 |
| Peugh, JL | 1 |
| Coffey, CS | 4 |
| Chamberlin, LA | 4 |
| Ecklund, D | 1 |
| Klingner, E | 1 |
| Yankey, J | 1 |
| Korbee, LL | 4 |
| Kabbouche, M | 1 |
| Kacperski, J | 5 |
| Porter, LL | 3 |
| Reidy, BL | 2 |
| Hershey, AD | 9 |
| Powers, SW | 9 |
| Lampl, C | 3 |
| Versijpt, J | 2 |
| Amin, FM | 1 |
| Deligianni, CI | 2 |
| Gil-Gouveia, R | 2 |
| Jassal, T | 2 |
| MaassenVanDenBrink, A | 2 |
| Ornello, R | 1 |
| Paungarttner, J | 1 |
| Sanchez-Del-Rio, M | 2 |
| Reuter, U | 2 |
| Uluduz, D | 2 |
| de Vries, T | 1 |
| Zeraatkar, D | 2 |
| Sacco, S | 2 |
| Domínguez-Durán, E | 1 |
| Montilla-Ibáñez, MA | 1 |
| Álvarez-Morujo de Sande, MG | 1 |
| Domènech-Vadillo, E | 1 |
| Bécares-Martínez, C | 1 |
| González-Aguado, R | 1 |
| Guerra-Jiménez, G | 1 |
| Rettig, EK | 1 |
| Ergun, G | 1 |
| Warfield, JR | 1 |
| Slater, SK | 4 |
| LeCates, SL | 4 |
| Kabbouche, MA | 6 |
| Kikui, S | 1 |
| Miyahara, J | 1 |
| Sugiyama, H | 1 |
| Kohashi, M | 1 |
| Ota, K | 1 |
| Danno, D | 1 |
| Kashiwaya, Y | 1 |
| Takeshima, T | 1 |
| Peugh, J | 3 |
| Ecklund, DJ | 2 |
| Klingner, EA | 2 |
| Yankey, JW | 2 |
| Ahmad, S | 1 |
| Chaput, JP | 1 |
| Vrignaud, L | 1 |
| Simon, C | 1 |
| Agier, MS | 1 |
| Bejan-Angoulvant, T | 1 |
| Bouquet, E | 1 |
| Beau-Salinas, F | 1 |
| Jonville-Béra, AP | 1 |
| Bazarsky, A | 1 |
| Prakash, S | 1 |
| Adroja, B | 1 |
| Parekh, H | 1 |
| Tripathi, GM | 2 |
| Isaacs, D | 1 |
| Patterson-Gentile, C | 1 |
| Szperka, CL | 1 |
| Hawks, M | 1 |
| Mounsey, A | 1 |
| Bruno, MAD | 1 |
| Krymchantowski, AV | 2 |
| May, A | 1 |
| Bhoi, SK | 2 |
| Israil, A | 1 |
| Ahmed, S | 1 |
| Rahman, KM | 1 |
| Uddin, MJ | 1 |
| Dey, SK | 1 |
| Battacharjee, M | 1 |
| Mondal, G | 1 |
| Ali, MA | 1 |
| Alam, MN | 1 |
| Miah, AH | 1 |
| Uddin, MS | 1 |
| Eklund, DD | 1 |
| Liang, J | 2 |
| Liu, X | 1 |
| Pan, M | 1 |
| Dai, W | 1 |
| Dong, Z | 2 |
| Wang, X | 2 |
| Liu, R | 2 |
| Zheng, J | 1 |
| Yu, S | 2 |
| Connelly, M | 1 |
| Kashikar-Zuck, SM | 3 |
| Allen, JR | 4 |
| Zafar, M | 3 |
| O'Brien, HL | 4 |
| Shenk, CE | 3 |
| Rausch, JR | 2 |
| Brainard, T | 1 |
| Beltramone, M | 1 |
| Donnet, A | 1 |
| Kovacic, K | 1 |
| Miranda, A | 1 |
| Chelimsky, G | 1 |
| Williams, S | 1 |
| Simpson, P | 1 |
| Li, BU | 1 |
| Cayir, A | 1 |
| Turan, MI | 1 |
| Tan, H | 1 |
| Agius, AM | 1 |
| Jones, NS | 1 |
| Muscat, R | 1 |
| Santiago, MD | 1 |
| Carvalho, Dde S | 1 |
| Gabbai, AA | 1 |
| Pinto, MM | 1 |
| Moutran, AR | 1 |
| Villa, TR | 1 |
| Banzi, R | 1 |
| Cusi, C | 1 |
| Randazzo, C | 1 |
| Sterzi, R | 1 |
| Tedesco, D | 1 |
| Moja, L | 1 |
| Linde, M | 2 |
| Steiner, TJ | 2 |
| Chisholm, D | 1 |
| Kroner, JW | 3 |
| Kroon Van Diest, AM | 3 |
| Gonçalves, AL | 1 |
| Martini Ferreira, A | 1 |
| Ribeiro, RT | 1 |
| Zukerman, E | 1 |
| Cipolla-Neto, J | 1 |
| Peres, MF | 1 |
| Atasayar, G | 1 |
| Eryilmaz, IE | 1 |
| Karli, N | 1 |
| Egeli, U | 1 |
| Zarifoglu, M | 1 |
| Cecener, G | 1 |
| Taskapilioglu, O | 1 |
| Tunca, B | 1 |
| Yildirim, O | 1 |
| Ak, S | 1 |
| Tezcan, G | 1 |
| Can, FE | 1 |
| Markus, TE | 1 |
| Moad, B | 1 |
| Haimi-Cohen, Y | 2 |
| Zeharia, A | 2 |
| Rosenberg, K | 1 |
| Ramsey, RR | 1 |
| Kashikar-Zuck, S | 1 |
| Slater, S | 1 |
| Hommel, K | 1 |
| LeCates, S | 1 |
| He, A | 1 |
| Song, D | 1 |
| Zhang, L | 1 |
| Li, C | 1 |
| Dalrymple, RA | 1 |
| Wacogne, I | 1 |
| Keskinbora, K | 1 |
| Aydinli, I | 1 |
| Evers, S | 1 |
| Kung, TA | 1 |
| Totonchi, A | 1 |
| Eshraghi, Y | 1 |
| Scher, MS | 1 |
| Gosain, AK | 1 |
| Yaldo, AZ | 1 |
| Wertz, DA | 1 |
| Rupnow, MF | 1 |
| Quimbo, RM | 1 |
| Sri-udomkajorn, S | 1 |
| Ruangsuwan, S | 1 |
| Dodick, DW | 1 |
| Freitag, F | 1 |
| Banks, J | 1 |
| Saper, J | 1 |
| Xiang, J | 2 |
| Rupnow, M | 1 |
| Biondi, D | 1 |
| Greenberg, SJ | 1 |
| Hulihan, J | 2 |
| Huber, G | 1 |
| Adl, J | 1 |
| Luthringshausen, G | 1 |
| Franz, G | 1 |
| Marecek, S | 1 |
| Weber, J | 1 |
| Baumhackl, U | 1 |
| Mueller, T | 1 |
| Bigal, ME | 1 |
| Lipton, RB | 1 |
| Biondi, DM | 1 |
| Evans, RW | 2 |
| Hirfanoglu, T | 1 |
| Serdaroglu, A | 1 |
| Gulbahar, O | 1 |
| Cansu, A | 1 |
| Nagata, E | 1 |
| Firnhaber, JM | 1 |
| Rickett, K | 1 |
| Supiot, F | 1 |
| Yan, L | 1 |
| Wang, Q | 1 |
| Fu, Q | 1 |
| Ye, Q | 1 |
| Xiao, H | 1 |
| Wan, Q | 1 |
| Magalhães, E | 1 |
| Menezes, C | 1 |
| Cardeal, M | 1 |
| Melo, A | 1 |
| Tepper, SJ | 1 |
| Couch, JR | 5 |
| Caproni, S | 1 |
| Corbelli, I | 1 |
| Pini, LA | 1 |
| Cupini, ML | 1 |
| Calabresi, P | 1 |
| Sarchielli, P | 1 |
| Liao, KY | 1 |
| Chang, FY | 1 |
| Wu, LT | 1 |
| Wu, TC | 1 |
| Taylor, J | 1 |
| Goodkin, HP | 1 |
| Bendtsen, L | 1 |
| Chen, X | 1 |
| Li, Z | 1 |
| Straube, A | 1 |
| Gaul, C | 1 |
| Rizzoli, PB | 1 |
| Pascual, J | 2 |
| Eidlitz-Markus, T | 1 |
| Dlugatch, Y | 1 |
| Goldberg-Stern, H | 1 |
| Silva, MT | 1 |
| Barbosa, JS | 1 |
| Alves, LA | 1 |
| Silberstein, SD | 1 |
| Winner, PK | 1 |
| Chmiel, JJ | 1 |
| Pringsheim, T | 1 |
| Diksic, M | 1 |
| Dobson, C | 1 |
| Nguyen, K | 1 |
| Hamel, E | 1 |
| Spry, H | 1 |
| McDiarmid, T | 1 |
| Mayer, J | 1 |
| Stanton, RN | 1 |
| Ignatov, IuD | 1 |
| Skoromets, AA | 2 |
| Amelin, AV | 2 |
| Lewis, DW | 1 |
| Diamond, S | 1 |
| Scott, D | 1 |
| Jones, V | 1 |
| Croissant, B | 1 |
| Brosi, K | 1 |
| Hermann, D | 1 |
| Mann, K | 1 |
| Rampello, L | 1 |
| Alvano, A | 1 |
| Chiechio, S | 1 |
| Malaguarnera, M | 1 |
| Raffaele, R | 1 |
| Vecchio, I | 1 |
| Nicoletti, F | 1 |
| Grazzi, L | 1 |
| Bulut, S | 2 |
| Berilgen, MS | 2 |
| Baran, A | 1 |
| Tekatas, A | 2 |
| Atmaca, M | 1 |
| Mungen, B | 2 |
| Mannix, LK | 1 |
| Láinez, MJ | 1 |
| Leira, R | 1 |
| Khromov, A | 1 |
| Segal, M | 1 |
| Nissinoff, J | 1 |
| Fast, A | 1 |
| Gonen, M | 1 |
| Dag, E | 1 |
| Kwiecień, J | 1 |
| Piasecki, L | 1 |
| Kasner, J | 1 |
| Karczewska, K | 1 |
| Hattori, M | 1 |
| Uematsu, N | 1 |
| Nakazawa, H | 1 |
| Matsukawa, N | 1 |
| Yamawaki, T | 1 |
| Ojika, K | 1 |
| Arnold, G | 1 |
| Schuh-Hofer, S | 1 |
| Mueller, LL | 1 |
| Ramchandren, S | 1 |
| Liebeskind, DS | 1 |
| Jürgens, TP | 1 |
| Leinisch, E | 1 |
| Koch, HJ | 1 |
| Gasbarri, A | 1 |
| Arnone, B | 1 |
| Pompili, A | 1 |
| Cifariello, A | 1 |
| Marini, C | 1 |
| Tavares, MC | 1 |
| Tomaz, C | 1 |
| Keays, AC | 1 |
| Neher, JO | 1 |
| Safranek, S | 1 |
| Webb, CW | 1 |
| Martin, MJ | 1 |
| Ziegler, DK | 6 |
| Damasio, H | 1 |
| Boiardi, A | 1 |
| Picotti, GB | 1 |
| Di Giulio, AM | 1 |
| Bussone, G | 1 |
| Galva, MD | 1 |
| La Mantia, L | 1 |
| Mantegazza, P | 1 |
| Sacquegna, T | 1 |
| Baldrati, A | 1 |
| D'Alessandro, R | 1 |
| De Carolis, P | 1 |
| Cortelli, P | 1 |
| Santucci, M | 1 |
| Lugaresi, E | 1 |
| Fozard, JR | 1 |
| Kudrow, L | 1 |
| Sorge, F | 1 |
| Barone, P | 1 |
| Steardo, L | 1 |
| Romano, MR | 1 |
| Raskin, NH | 1 |
| Schwartz, RK | 1 |
| Bánk, J | 1 |
| Barlow, CF | 1 |
| Hurwitz, A | 2 |
| Preskorn, S | 1 |
| Hassanein, R | 2 |
| Seim, J | 1 |
| Nicolodi, M | 1 |
| Sicuteri, F | 1 |
| Ramadan, NM | 1 |
| Schultz, LL | 1 |
| Gilkey, SJ | 1 |
| Titus, F | 1 |
| Nelson, CF | 1 |
| Bronfort, G | 1 |
| Evans, R | 1 |
| Boline, P | 1 |
| Goldsmith, C | 1 |
| Anderson, AV | 1 |
| Oguzhanoglu, A | 1 |
| Sahiner, T | 1 |
| Kurt, T | 1 |
| Akalin, O | 1 |
| Barth, N | 1 |
| Riegels, M | 1 |
| Hebebrand, J | 1 |
| Remschmidt, H | 1 |
| Korenko, LA | 1 |
| Tumelevich, BCh | 1 |
| Gonchar, MA | 1 |
| Massiou, H | 3 |
| Terrón, JA | 1 |
| Hassanein, RS | 4 |
| Deliganis, AV | 1 |
| Peroutka, SJ | 1 |
| Hering, R | 1 |
| Weiss, HD | 1 |
| Stern, BJ | 1 |
| Goldberg, J | 1 |
| Nazarian, SM | 1 |
| Jay, WM | 1 |
| Elser, JM | 1 |
| Woody, RC | 1 |
| Bousser, MG | 2 |
| Kodanaz, HA | 1 |
| Preskorn, SH | 1 |
| Mason, J | 1 |
| van der Kruijk, RA | 1 |
| Vecht, CJ | 1 |
| Pfaffenrath, V | 1 |
| Kellhammer, U | 1 |
| Pöllmann, W | 1 |
| Martucci, N | 1 |
| Manna, V | 1 |
| Agnoli, A | 1 |
| Gunderson, CH | 1 |
| Gomersall, JD | 1 |
| Stuart, A | 1 |
| Sanger, MD | 1 |
| Lance, JW | 1 |
| Curran, DA | 1 |
| Anthony, M | 1 |
| Viëtor, WP | 1 |
| Zwart, JM | 1 |
| Mahloudji, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Aerobic Exercise Training (AET) on the Large Intracranial and Extracranial Cerebral Arteries and the Cognitive and Motor Functions in Post Stroke Patients.[NCT05706168] | 120 participants (Anticipated) | Interventional | 2023-02-10 | Recruiting | |||
| Drug and Non-Drug Treatment of Pediatric Chronic Headache[NCT00389038] | Phase 3 | 132 participants (Anticipated) | Interventional | 2006-10-31 | Active, not recruiting | ||
| Amitriptyline and Topiramate in the Prevention of Childhood Migraine[NCT01581281] | Phase 3 | 488 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to Interim assessment provided sufficient data to answer study questions) | ||
| Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department[NCT03576820] | Phase 3 | 50 participants (Anticipated) | Interventional | 2018-10-15 | Recruiting | ||
| Comparison of Efficacy Between Combination of Amitriptyline-propranolol and Pizotifen for Migraine Prophylaxis: A Single-blind Randomized Controlled Trial[NCT06158230] | Phase 2 | 140 participants (Actual) | Interventional | 2023-03-19 | Active, not recruiting | ||
| Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Randomized Double Blinded Placebo Cross-over Study in the Pediatric Pain Population[NCT03055767] | Phase 2 | 17 participants (Actual) | Interventional | 2017-03-01 | Completed | ||
| Impact of Physical Activity for Chronic Pelvic Pain[NCT02867774] | 22 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| Efficacy of Physiotherapy Intervention Among University Students With Migraine Symptoms[NCT05741775] | Early Phase 1 | 87 participants (Anticipated) | Interventional | 2022-09-18 | Recruiting | ||
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| The Effects of Spinal Manipulative Therapy on Postactivation Potentiation[NCT02848456] | 20 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The PedMIDAS scale which evaluated the impact of headaches in school, home, play, and social activities, is comprised of six items that pertain to days missed in various activities over the past 90 days. Questions were answered by the youth in consultation with their parents and reviewed by study staff. The PedMIDAS scale was administered at baseline (covering the three months prior to enrollment) and at the 24-week endpoint visit (the end of the maintenance period, covering three months of enrollment). A total PedMIDAS score (sum of items 1-6) was used in this trial. Scores range from 0-240; with a score of 0-10 indicating no disability, 11-30 mild disability, 31-50 moderate disability, and more than 50 severe disability in daily activities. The main outcome measure for this comparison will be the difference in the baseline and endpoint (24 week) PedMIDAS total scores for:~Amitriptyline vs. Placebo~Topiramate vs. Placebo~Amitriptyline vs Topiramate" (NCT01581281)
Timeframe: baseline and 24 week endpoint
| Intervention | units on a scale (Mean) |
|---|---|
| Topiramate | -26.8 |
| Placebo | -22.6 |
| Amitriptyline | -22.5 |
"This outcomes measure examines whether the rate of absolute number of headache days, per 28 day period, differs between treatment groups over time. This was assessed longitudinally based on the actual number of headache days from the 28 days prior to randomization to the last 28 days of this 24 week trial. The change in absolute headache days was compared between:~Amitriptyline vs. placebo~Topiramate vs. placebo~Amitriptyline vs. Topiramate" (NCT01581281)
Timeframe: 4 week baseline period and last 4 weeks of the 24-week trial
| Intervention | days (Mean) |
|---|---|
| Topiramate | -6.7 |
| Placebo | -5.9 |
| Amitriptyline | -6.7 |
"The primary endpoint was a ≥ 50% reduction in headache frequency from the 28 days (4 weeks) baseline period prior to randomization to the last 28 days (4 weeks) of the trial. Headache frequency was defined as the number of days with headache for a given four week 28 day (4 week) period. A headache day was defined as any day during which any headache occurs within a 24 hour period, starting and ending at midnight.~For each participant, the primary endpoint involved a determination of whether a 50% or greater reduction in headache frequency was observed during the last 4 weeks of active treatment as compared with the headache frequency during the 4-week baseline period. Results were compared across the three treatment groups." (NCT01581281)
Timeframe: 4 week baseline period and last 4 weeks of the 24-week trial
| Intervention | Participants (Count of Participants) |
|---|---|
| Topiramate | 72 |
| Placebo | 40 |
| Amitriptyline | 69 |
To determine if amitriptyline or topiramate differ from placebo on the occurrence of treatment emergent serious adverse events. (NCT01581281)
Timeframe: 24 weeks of the trial
| Intervention | serious adverse events (Number) |
|---|---|
| Topiramate | 4 |
| Placebo | 2 |
| Amitriptyline | 6 |
To assess tolerability, the percentage of subjects who complete the entire 24-week treatment period will be estimated in each of the three groups. (NCT01581281)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Topiramate | 102 |
| Placebo | 59 |
| Amitriptyline | 106 |
Open-Label Period" (NCT03055767)
Timeframe: Duration of migraine in hours during the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.
| Intervention | Duration of migraine in hours during the open-labe (hours) |
|---|---|
| Cross-Over Period | Median |
| "Open-Label Period | Median |
Open-label Period" (NCT03055767)
Timeframe: The frequency of migraines during the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.
| Intervention | The frequency of migraines during the open-label p (days) |
|---|---|
| "Open-Label Period | Median |
Open-Label Period" (NCT03055767)
Timeframe: "Intensity of migraines during the the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.~Intensity based on 0-10 Pain Numeric Rating Score (NRS). The higher the score, the more intense the pain."
| Intervention | "Intensity of migraines during the the open-label (units on a scale) |
|---|---|
| Cross-Over Period | Median |
| "Open-Label Period | Median |
Open-Label Period" (NCT03055767)
Timeframe: "The PedMIDAS the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.~The PedMIDAS consists of 6 questions: 3 addressing school attendance and functioning, and 3 evaluating participation in events outside of
| Intervention | "The PedMIDAS the open-label period (2 additional (score on a scale) |
|---|---|
| Cross-Over Period | Median |
| "Open-Label Period | Median |
Number of concomitant headache medications taken (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | number taken (Median) |
|---|---|
| "Baseline Period | 3 |
| Botox Period | 1 |
| Placebo Period | 2 |
Subject reported having difficulty sleeping (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | Participants (Count of Participants) |
|---|---|
| "Baseline Period | 12 |
| Botox Period | 5 |
| Placebo Period | 11 |
The duration of benefit in weeks (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | weeks (Median) |
|---|---|
| Botox Period | 4 |
| Placebo Period | 0 |
Subject visited an Emergency Department (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | Participants (Count of Participants) |
|---|---|
| "Baseline Period | 8 |
| Botox Period | 2 |
| Placebo Period | 3 |
The frequency of migraines in days. (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | days (Median) |
|---|---|
| "Baseline Period | 28 |
| Botox Period | 20 |
| Placebo Period | 28 |
"Improvement of functionality as determined by their Pediatric Migraine Disability Score (PedMIDAS). The PedMIDAS consists of 6 questions: 3 addressing school attendance and functioning, and 3 evaluating participation in events outside of school. The questionnaire is based on the patient's recall of the previous 3 months.~The questionnaire produces a raw score (0-10, 11-30, 31-50, >50) corresponding to a disability grade with increasing severity (little to non, mild, moderate, and severe) which was coded (1, 2, 3, and 4)." (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | score on a scale (Median) |
|---|---|
| Botox Period | 1 |
| Placebo Period | 0 |
Subject is home schooled full-time. (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post, respective intervention
| Intervention | Participants (Count of Participants) |
|---|---|
| "Baseline Period | 2 |
| Botox Period | 2 |
| Placebo Period | 2 |
Admission to hospital (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | Participants (Count of Participants) |
|---|---|
| "Baseline Period | 8 |
| Botox Period | 0 |
| Placebo Period | 2 |
Median intensity of migraines based on 0-10 Pain Numeric Rating Score (NRS). The higher the score, the more intense the pain. (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | units on a scale (Median) |
|---|---|
| "Baseline Period | 8 |
| Botox Period | 5 |
| Placebo Period | 7 |
Duration of migraines in hours. (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | hours (Median) |
|---|---|
| "Baseline Period | 24 |
| Botox Period | 10 |
| Placebo Period | 24 |
"Pediatric Migraine Disability Score consists of 6 questions: 3 addressing school attendance and functioning, and 3 evaluating participation in events outside of school. The questionnaire is based on the patient's recall of the previous 3 months.~The questionnaire produces a raw score (0-10, 11-30, 31-50, >50) corresponding to a disability grade with increasing severity (little to non, mild, moderate, and severe) which was coded (1, 2, 3, and 4)." (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | score on a scale (Median) |
|---|---|
| "Baseline Period | 4 |
| Botox Period | 3 |
| Placebo Period | 4 |
Subject is enrolled in a school plan such as IEP, 504 plan, or similar modified school schedule. (NCT03055767)
Timeframe: Baseline (4 weeks) and 12 weeks post each, respective intervention
| Intervention | Participants (Count of Participants) |
|---|---|
| "Baseline Period | 11 |
| Botox Period | 10 |
| Placebo Period | 10 |
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
31 reviews available for amitriptyline and Migraine Disorders
| Article | Year |
|---|---|
What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials.
Topics: Adult; Amitriptyline; Exercise; Female; Humans; Male; Migraine Disorders; Network Meta-Analysis; Res | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline.
Topics: Adult; Amitriptyline; Headache; Humans; Migraine Disorders; Transcription Factors | 2023 |
The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Gabapentin; Humans; M | 2023 |
New Developments in the Prophylactic Drug Treatment of Pediatric Migraine: What Is New in 2017 and Where Does It Leave Us?
Topics: Amitriptyline; Analgesics, Non-Narcotic; Child; Controlled Clinical Trials as Topic; Fructose; Heada | 2017 |
The Changing Landscape of Pediatric Migraine Therapy: A Review.
Topics: Adolescent; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Anti-Inflammatory | 2018 |
Hints on Diagnosing and Treating Headache.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Antihypertensive Agents; Headache; Humans; Metoprolol; Migr | 2018 |
Prevention of migraine attacks. First-choice treatments.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tric | 2015 |
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
Topics: Adult; Amitriptyline; Citalopram; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; | 2015 |
[Update on Current Care Guideline: Migraine].
Topics: Acetaminophen; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opi | 2015 |
Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis.
Topics: Adult; Amines; Amitriptyline; Anticonvulsants; Cyclohexanecarboxylic Acids; Dizziness; Female; Fruct | 2017 |
[Alternatives to beta blockers in preventive migraine treatment].
Topics: Adrenergic beta-Antagonists; Adult; Amitriptyline; Anticonvulsants; Botulinum Toxins, Type A; Calciu | 2008 |
[Antidepressants in migraine prophylaxis].
Topics: Amitriptyline; Antidepressive Agents; Clinical Trials as Topic; Depression; Drug Administration Sche | 2009 |
Clinical inquiries. What are the best prophylactic drugs for migraine?
Topics: Adrenergic beta-Antagonists; Amitriptyline; Evidence-Based Medicine; Family Practice; Female; Fructo | 2009 |
Dizziness and vertigo in the adolescent.
Topics: Adolescent; Amitriptyline; Analgesics, Non-Narcotic; Chronic Disease; Dizziness; Female; Headache; H | 2011 |
[Chronic migraine: treatment].
Topics: Amitriptyline; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antihypertensiv | 2012 |
Clinical inquiries. What medication best prevents migraine in children?
Topics: Amitriptyline; Child; Evidence-Based Medicine; Humans; Migraine Disorders; Propranolol; Valproic Aci | 2003 |
[Current views on migraine and anti-migraine preparations].
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Amitriptyline; Analgesics; Analgesics, No | 2003 |
Primary headaches in children and adolescents.
Topics: Adolescent; Amitriptyline; Antidepressive Agents, Tricyclic; Child; Headache Disorders; Humans; Migr | 2004 |
Clinical advances in the preventive treatment of migraine.
Topics: Amitriptyline; Fructose; Humans; Migraine Disorders; Propranolol; Topiramate; Valproic Acid | 2004 |
[Comorbidities in migraine patients].
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Anxiety Disorders; Carotid Artery, | 2007 |
Diagnosing and managing migraine headache.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Caffeine; Food; Humans; Migraine Disorders; Migraine withou | 2007 |
[A clinical challenge. Pragmatic treatment of migraine and concomitant depression].
Topics: Amitriptyline; Analgesics, Non-Narcotic; Antidepressive Agents, Second-Generation; Antidepressive Ag | 2008 |
Muscle-contraction (tension) headache.
Topics: Amitriptyline; Anxiety; Biofeedback, Psychology; Conflict, Psychological; Depressive Disorder; Elect | 1983 |
An overview of the classification, causes, and treatment of headache.
Topics: Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Biofeedback, Psychology; Cerebrovascula | 1984 |
Drug management of adult vascular headaches (migraine and cluster headache): Part II--Prevention and attacks.
Topics: Adult; Amitriptyline; Belladonna Alkaloids; Cluster Headache; Cyproheptadine; Drug Combinations; Erg | 1984 |
Basic mechanisms of antimigraine drugs.
Topics: Amitriptyline; Animals; Chlorpromazine; Humans; Methysergide; Metoclopramide; Migraine Disorders; Pr | 1982 |
Migraine prophylactic drugs: proof of efficacy, utilization and cost.
Topics: Adult; Amitriptyline; Female; Humans; Male; Migraine Disorders; Propranolol; Verapamil | 1997 |
["Cyclic vomiting" in childhood and adolescence].
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Behavior Therapy; Child of Impaired Parents; Child, Pre | 2000 |
[Prophylactic treatments of migraine].
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants | 2000 |
Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine?
Topics: Amitriptyline; Animals; Cyproheptadine; Humans; Lisuride; Migraine Disorders; Models, Biological; Re | 2002 |
46 trials available for amitriptyline and Migraine Disorders
| Article | Year |
|---|---|
A Randomized Controlled Trial of High Rate rTMS Versus rTMS and Amitriptyline in Chronic Migraine.
Topics: Adolescent; Amitriptyline; Headache; Humans; Migraine Disorders; Transcranial Magnetic Stimulation; | 2021 |
Venlafaxine can reduce the migraine attacks as well as amitriptyline: A noninferiority randomized trial.
Topics: Adult; Amitriptyline; Drug-Related Side Effects and Adverse Reactions; Female; Headache; Humans; Mal | 2022 |
Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments.
Topics: Adolescent; Amitriptyline; Child; Double-Blind Method; Fructose; Headache; Headache Disorders; Human | 2023 |
Predictors of Improvement in Pediatric Chronic Migraine: Results from the Cognitive-Behavioral Therapy and Amitriptyline Trial.
Topics: Adolescent; Amitriptyline; Child; Cognitive Behavioral Therapy; Headache; Humans; Migraine Disorders | 2022 |
Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial.
Topics: Adolescent; Amitriptyline; Child; Double-Blind Method; Headache; Headache Disorders; Humans; Migrain | 2022 |
Migraine in children.
Topics: Adolescent; Amitriptyline; Child; Female; Follow-Up Studies; Humans; Male; Migraine Disorders; Monit | 2018 |
Amitriptyline and intraoral devices for migraine prevention: a randomized comparative trial.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Female; Humans; Male; Migraine Disorders; Occlusal S | 2018 |
Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Cohort Studies; Delayed | 2013 |
Efficacy of amitriptyline, pizotifen and propranolol in the prevention of migraine.
Topics: Acetaminophen; Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Antiemetics; Child; Dompe | 2013 |
Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.
Topics: Adolescent; Amitriptyline; Analgesics; Child; Comparative Effectiveness Research; Double-Blind Metho | 2013 |
Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.
Topics: Adolescent; Amitriptyline; Analgesics; Child; Comparative Effectiveness Research; Double-Blind Metho | 2013 |
Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.
Topics: Adolescent; Amitriptyline; Analgesics; Child; Comparative Effectiveness Research; Double-Blind Metho | 2013 |
Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.
Topics: Adolescent; Amitriptyline; Analgesics; Child; Comparative Effectiveness Research; Double-Blind Metho | 2013 |
Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial.
Topics: Adolescent; Amitriptyline; Antidepressive Agents, Tricyclic; Child; Chronic Disease; Cognitive Behav | 2013 |
Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients.
Topics: Adolescent; Alkaline Phosphatase; Amitriptyline; Analgesics, Non-Narcotic; Analysis of Variance; Cal | 2014 |
Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Chronic Disease; Combined Modality Thera | 2014 |
Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Chronic Disease; Combined Modality Thera | 2014 |
Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Chronic Disease; Combined Modality Thera | 2014 |
Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Chronic Disease; Combined Modality Thera | 2014 |
Cognitive Behavioral Therapy plus Amitriptyline for Children and Adolescents with Chronic Migraine Reduces Headache Days to ≤4 Per Month.
Topics: Adolescent; Amitriptyline; Analgesics; Child; Cognitive Behavioral Therapy; Female; Humans; Male; Mi | 2016 |
Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention.
Topics: Adolescent; Adult; Aged; Amitriptyline; Double-Blind Method; Female; Follow-Up Studies; Humans; Male | 2016 |
Melatonin: Safe And Effective for the Prevention of Migraine Headache.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antioxidants; Humans; Mela | 2016 |
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.
Topics: Adolescent; Amitriptyline; Anticonvulsants; Child; Double-Blind Method; Fatigue; Female; Fructose; H | 2017 |
Trajectory of Improvement in Children and Adolescents With Chronic Migraine: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial.
Topics: Adolescent; Amitriptyline; Analgesics, Non-Narcotic; Child; Chronic Disease; Cognitive Behavioral Th | 2017 |
Treatment Adherence in Child and Adolescent Chronic Migraine Patients: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial.
Topics: Adolescent; Amitriptyline; Analgesics, Non-Narcotic; Child; Chronic Disease; Cognitive Behavioral Th | 2017 |
A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine.
Topics: Adult; Amitriptyline; Anticonvulsants; Antidepressive Agents, Tricyclic; Constipation; Disorders of | 2008 |
Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
Topics: Adult; Amitriptyline; Body Weight; Central Nervous System Agents; Disability Evaluation; Double-Blin | 2009 |
Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Delayed-Action Preparations; Female; Humans; Logisti | 2009 |
Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Biomarkers; Blood Pressure; Cardiovascular Diseases; | 2009 |
Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.
Topics: Adolescent; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Botulinum Toxins, Type A; Chroni | 2010 |
Amitriptyline in the prophylactic treatment of migraine and chronic daily headache.
Topics: Adolescent; Adult; Aged; Aging; Amitriptyline; Antidepressive Agents, Tricyclic; Double-Blind Method | 2011 |
Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Female; Flunarizine; Humans; Hypothalamus; Male; Mid | 2011 |
Allodynia in migraine: clinical observation and role of prophylactic therapy.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Child; Comorbidity; Female; Humans; Hype | 2013 |
Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Constipation; Double-Blind Method; Drug Therapy, | 2002 |
Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache.
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents; Citalopram; Comorbidity; Depressi | 2004 |
Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Cross-Over Studies; Cyclohexanols; D | 2004 |
Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Body Mass Index; C-Peptide; Female; Flunariz | 2005 |
Emotional memory and migraine: effects of amitriptyline and sex related difference.
Topics: Adult; Affect; Amitriptyline; Analysis of Variance; Antidepressive Agents, Tricyclic; Arousal; Chron | 2008 |
A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis.
Topics: Adult; Amitriptyline; Female; Fluvoxamine; Humans; Male; Middle Aged; Migraine Disorders | 1994 |
Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects.
Topics: Adolescent; Adult; Amitriptyline; Blood Pressure; Chromatography, High Pressure Liquid; Discriminant | 1993 |
Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy.
Topics: 5-Hydroxytryptophan; Amitriptyline; Antidepressive Agents, Tricyclic; Anxiety; Drug Therapy, Combina | 1996 |
The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache.
Topics: Adolescent; Adult; Aged; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Combined Modal | 1998 |
Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches.
Topics: Adult; Amitriptyline; Antidepressive Agents; Dose-Response Relationship, Drug; Drug Administration S | 1999 |
[A comparative efficiency of amitriptyline, fluoxetine and maprotiline in prevention of migraine in attack-free period].
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Analgesics, Non-Narcotic; Female; | 2000 |
Amitriptyline in migraine prophylaxis.
Topics: Amitriptyline; Depression; Double-Blind Method; Humans; Migraine Disorders | 1979 |
Migraine and depression: effect of amitriptyline prophylaxis.
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Drug Evaluation; Humans; Migraine Disorders | 1976 |
Abrupt outpatient withdrawal of medication in analgesic-abusing migraineurs.
Topics: Adult; Amitriptyline; Analgesics; Caffeine; Ergotamine; Evaluation Studies as Topic; Female; Follow- | 1991 |
Migraine prophylaxis. A comparison of propranolol and amitriptyline.
Topics: Adult; Amitriptyline; Anxiety; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; M | 1987 |
Antidepressant drugs and migraine.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depression; Female | 1985 |
Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial.
Topics: Adult; Aged; Amitriptyline; Evaluation Studies as Topic; Fatigue; Female; Humans; Male; Middle Aged; | 1973 |
The treatment of anxiety and depression in the allergic patient.
Topics: Adolescent; Adult; Aged; Amitriptyline; Angioedema; Anxiety; Asthma; Clinical Trials as Topic; Depre | 1969 |
Investigations into the mechanism and treatment of chronic headache.
Topics: Amitriptyline; Clinical Trials as Topic; Headache; Humans; Hydroxyindoleacetic Acid; Hypertension; M | 1965 |
67 other studies available for amitriptyline and Migraine Disorders
| Article | Year |
|---|---|
Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.
Topics: Amitriptyline; COVID-19; Female; Headache; Humans; Male; Migraine Disorders; Nausea; Retrospective S | 2022 |
Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug.
Topics: Acetazolamide; Amitriptyline; Analgesics; Central Nervous System Agents; Flunarizine; Humans; Migrai | 2020 |
A Combination of Indomethacin Farnesyl and Amitriptyline Is Effective for Continuous Interictal Pain with Probable Chronic Paroxysmal Hemicrania.
Topics: Adult; Amitriptyline; Female; Headache; Humans; Indomethacin; Migraine Disorders; Paroxysmal Hemicra | 2022 |
Amitriptyline and topiramate do not demonstrate benefit in pediatric migraine.
Topics: Amitriptyline; Child; Fructose; Humans; Migraine Disorders; Topiramate | 2017 |
Screen time associated with adolescent obesity and obesity risk factors.
Topics: Adolescent; Amitriptyline; Child; Humans; Migraine Disorders; Obesity; Pediatric Obesity; Risk Facto | 2017 |
[Drugs news].
Topics: Adolescent; Adult; Age Factors; Amitriptyline; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, N | 2017 |
Serotonin syndrome in patients with headache disorders.
Topics: Acetaminophen; Adult; Amitriptyline; Analgesics; Cluster Headache; Drug Therapy, Combination; Flunar | 2017 |
A study of oxidative stress in migraine with special reference to prophylactic therapy.
Topics: Adolescent; Adult; Aged; Amitriptyline; Analgesics, Non-Narcotic; Antioxidants; Female; Glutathione; | 2018 |
PURL: Treating migraines: It's different for kids.
Topics: Adolescent; Adult; Amitriptyline; Child; Humans; Migraine Disorders; Topiramate | 2018 |
Role of glutamate and its receptors in migraine with reference to amitriptyline and transcranial magnetic stimulation therapy.
Topics: Adolescent; Adult; Amitriptyline; Female; Glutamic Acid; Humans; Male; Middle Aged; Migraine Disorde | 2018 |
Blockade of Nav1.8 currents in nociceptive trigeminal neurons contributes to anti-trigeminovascular nociceptive effect of amitriptyline.
Topics: Afferent Pathways; Amitriptyline; Aniline Compounds; Animals; Blood Vessels; Disease Models, Animal; | 2014 |
Cognitive behavioral therapy for treatment of pediatric chronic migraine.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Female; Headache; Hum | 2013 |
Obstructive sleep apnea and tricyclic antidepressant use presenting as a pseudopheochromocytoma in an active duty sailor: a case report.
Topics: Adrenal Gland Neoplasms; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Diagnosis, Differen | 2014 |
Status migrainosus and migraine aura status in a French tertiary-care center: An 11-year retrospective analysis.
Topics: Adult; Aged; Amitriptyline; Cross-Sectional Studies; Female; Follow-Up Studies; France; Hospitalizat | 2014 |
Chronic idiopathic nausea of childhood.
Topics: Abdominal Pain; Adolescent; Amitriptyline; Antidepressive Agents, Tricyclic; Anxiety; Child; Chronic | 2014 |
Is 'sinus' pain really sinusitis?
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Diagnosis, Differential; Disease Management; Facial Pai | 2014 |
Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries.
Topics: Amitriptyline; China; Cost-Benefit Analysis; Fructose; Humans; Income; India; Medication Adherence; | 2015 |
Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.
Topics: Adult; Amitriptyline; ATP Binding Cassette Transporter, Subfamily B; Central Nervous System Agents; | 2016 |
Factors Influencing Response to Pharmacologic Treatment of Migraine in a Pediatric Headache Clinic.
Topics: Adolescent; Age Factors; Amitriptyline; Central Nervous System Agents; Child; Child, Preschool; Coho | 2016 |
Amitriptyline and topiramate are no better than placebo for childhood migraine.
Topics: Amitriptyline; Double-Blind Method; Fructose; Humans; Migraine Disorders; Topiramate; Treatment Outc | 2017 |
Review of pediatric migraine headaches refractory to medical management.
Topics: Adolescent; Amitriptyline; Analgesics, Non-Narcotic; Biofeedback, Psychology; Child; Female; Follow- | 2009 |
Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
Topics: Adult; Age Factors; Amitriptyline; Cohort Studies; Databases, Factual; Dose-Response Relationship, D | 2008 |
Short-term outcomes of tension type and migraine headache in children.
Topics: Adolescent; Amitriptyline; Analgesics, Non-Narcotic; Child; Child, Preschool; Female; Humans; Male; | 2008 |
Expert opinion: adherence to prophylactic migraine medication.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Expert Testimony; Female; Humans; Medication Adheren | 2009 |
Prophylactic drugs and cytokine and leptin levels in children with migraine.
Topics: Adolescent; Amitriptyline; Central Nervous System Agents; Child; Cyproheptadine; Cytokines; Female; | 2009 |
[Migraine in 2009: from attack to treatment].
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Behavior Therapy; Biofeedback, Psychology; Child; Europ | 2009 |
Amitriptyline inhibits currents and decreases the mRNA expression of voltage-gated sodium channels in cultured rat cortical neurons.
Topics: Action Potentials; Amitriptyline; Analgesics, Non-Narcotic; Animals; Cells, Cultured; Cerebral Corte | 2010 |
The role of prevention.
Topics: Amitriptyline; Headache; Humans; Migraine Disorders | 2010 |
Cyclic vomiting syndrome in Taiwanese children.
Topics: Adolescent; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Age of Onset; Amitriptyline; | 2011 |
[Preventive migraine drugs--they are indeed still working].
Topics: Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Humans; Migraine Disorders; Propranolol | 2011 |
The effects of OB-induced depression on nociceptive behaviors induced by electrical stimulation of the dura mater surrounding the superior sagittal sinus.
Topics: Amitriptyline; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dura Mater; Elect | 2011 |
[Chronic migraine: not well known but not rare!].
Topics: Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease; Femal | 2011 |
Talking about migraine.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Diet; Humans; Migraine Disorders; Phytotherapy; Ser | 2012 |
Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline.
Topics: Adolescent; Amitriptyline; Child; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; H | 2012 |
Migraine preventive medication reduces resource utilization.
Topics: Amitriptyline; Cohort Studies; Health Resources; Humans; Migraine Disorders; Practice Guidelines as | 2003 |
Selective decrease in serotonin synthesis rate in rat brainstem raphe nuclei following chronic administration of low doses of amitriptyline: an effect compatible with an anti-migraine effect.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Animals; Brain Stem; Male; Migraine Disorders; Raphe Nuclei | 2003 |
Prophylactic treatment of pediatric migraine.
Topics: Adolescent; Age Factors; Amitriptyline; Analgesics, Non-Narcotic; Child; Child, Preschool; Cyprohept | 2004 |
[Drug-induced headache and pain reduction medication with amitriptyline in an 11-year old pupil].
Topics: Amitriptyline; Analgesics; Antihypertensive Agents; Aspirin; Child; Dipyrone; Headache Disorders; Hu | 2004 |
Bending the rule of monotherapy for migraine prevention?
Topics: Adrenergic beta-Antagonists; Adult; Amitriptyline; Drug Therapy, Combination; Female; Humans; Migrai | 2005 |
Migraines linked to interferon-beta treatment of multiple sclerosis.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Female; Humans; Interferon-beta; Migraine Disorders; | 2005 |
[Abdominal migraine as a cause of chronic recurrent abdominal pain in a 9-years-old girl--case report].
Topics: Abdominal Pain; Amitriptyline; Analgesics, Non-Narcotic; Child; Chronic Disease; Diagnosis, Differen | 2005 |
Pharmacological prevention of migraine: to be considered case by case.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anticonvulsants; Antidepressive Agents; Cost-Benefit Ana | 2006 |
[An adult case of cyclic vomiting syndrome in which tricyclic antidepressant was effective].
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Humans; Male; Migraine Disorders; Periodicit | 2006 |
Headache in a patient with Klinefelter's syndrome and hyperostosis frontalis interna.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Humans; Hyperostosis Frontalis Interna; Ischemic Att | 2007 |
Clinical inquiries. Is osteopathic manipulation effective for headaches?
Topics: Amitriptyline; Analgesics, Non-Narcotic; Headache; Humans; Manipulation, Osteopathic; Migraine Disor | 2008 |
Platelet met-enkephalin immunoreactivity and 5-hydroxytryptamine concentrations in migraine patients: effects of 5-hydroxytryptophan, amitriptyline and chlorimipramine treatment.
Topics: 5-Hydroxytryptophan; Adult; Amitriptyline; Blood Platelets; Clomipramine; Enkephalin, Methionine; Fe | 1984 |
Migraine prophylaxis: prognostic significance of clinical factors.
Topics: Adolescent; Adult; Aged; Amitriptyline; Child; Child, Preschool; Female; Humans; Male; Methysergide; | 1983 |
Paradoxical effects of frequent analgesic use.
Topics: Adult; Amitriptyline; Analgesics; Drug Tolerance; Female; Headache; Humans; Hypnotics and Sedatives; | 1982 |
Amitriptyline as a prophylactic for migraine in children.
Topics: Amitriptyline; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders | 1982 |
Interval therapy of migraine: long-term results.
Topics: Adolescent; Adult; Aged; Amitriptyline; Cyproheptadine; Ergonovine; Ergotamine; Humans; Middle Aged; | 1980 |
Migraine in the infant and toddler.
Topics: Adolescent; Amitriptyline; Child; Child, Preschool; Diagnosis, Differential; Electroencephalography; | 1994 |
[The treatment of migraine].
Topics: Adrenergic beta-Antagonists; Amitriptyline; Calcium Channel Blockers; Dihydroergotamine; Ergotamine; | 1997 |
New "triptans" and other drugs for migraine.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 1998 |
Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects.
Topics: Amitriptyline; Depression; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Migraine Disord | 1976 |
5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy.
Topics: Adenylyl Cyclase Inhibitors; Amitriptyline; Animals; Cattle; Caudate Nucleus; Dihydroergotamine; Erg | 1991 |
Post-traumatic migraine: chronic migraine precipitated by minor head or neck trauma.
Topics: Adolescent; Adult; Amitriptyline; Chronic Disease; Craniocerebral Trauma; Female; Humans; Male; Midd | 1991 |
Intermittent unidirectional nystagmus.
Topics: Adult; Amitriptyline; Female; Humans; Migraine Disorders; Nystagmus, Pathologic; Periodicity | 1990 |
Migraine headache in the infant and young child.
Topics: Amitriptyline; Child, Preschool; Female; Humans; Imipramine; Infant; Male; Migraine Disorders; Ophth | 1990 |
[Antimigrainous agents. General considerations and treatment of the crisis].
Topics: Acupuncture Therapy; Amitriptyline; Analgesics; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antie | 1986 |
[Antimigrainous agents used in maintenance treatment].
Topics: Adrenergic beta-Antagonists; Amitriptyline; Aspirin; Benzoxepins; Calcium Channel Blockers; Cinnariz | 1986 |
[Status migrainosus, a separate variant of migraine?].
Topics: Adult; Aged; Amitriptyline; Depression; Female; Humans; Middle Aged; Migraine Disorders; Time Factor | 1987 |
Combination headache: practical experience with a combination of a beta-blocker and an antidepressive.
Topics: Adult; Amitriptyline; Cluster Headache; Drug Therapy, Combination; Female; Headache; Humans; Male; M | 1986 |
Management of the migraine patient.
Topics: Amitriptyline; Analgesics; Diagnosis, Differential; Diet; Ergotamine; Humans; Hypnotics and Sedative | 1986 |
Evaluation of amitriptyline in migraine prophylaxis.
Topics: Amitriptyline; Depression; Drug Evaluation; Humans; Migraine Disorders | 1974 |
Migraine. Diagnostic and therapeutic aspects.
Topics: Amitriptyline; Analgesics; Cerebrovascular Circulation; Ergotamine; Humans; Methysergide; Migraine D | 1974 |
[Psychogenic headache and its treatment with hypnosis and autogenic training].
Topics: Amitriptyline; Autogenic Training; Headache; Hypnosis; Migraine Disorders; Physician-Patient Relatio | 1968 |
Prevention of migraine.
Topics: Amitriptyline; Humans; Migraine Disorders | 1969 |